Skip to main content
. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669

Figure 1.

Figure 1

(A) Mean per cent change in MASES up to week 156 and (B) patients achieving a MASES of 0 up to week 156. Data as observed in patients with pre-existing enthesitis. Analyses include all patient data, including the placebo-controlled period, regardless of when patients started taking apremilast (baseline, week 16 or week 24). MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; n/m, number of responders/number of patients with sufficient data for evaluation.